ClinicalTrials.gg

Program

cytisine

Also written as “Cytisinicline”, “Cytisine” and “cytisinicline”.

Its studies are mostly in Smoking Cessation · Vaping · Renal Insufficiency, led by Achieve Life Sciences.

Furthest: phase 3, since Sep 25, 202013 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Achieve Life Sciences131 open or runningphase 3since Sep 25, 2020Aug 25, 2017none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2017First study: phase 1 study in Smoking CessationFirst studyNCT03268343 · 24 enrolled · United Kingdom
  2. Sep 28, 2017Phase 2 study in Smoking CessationNCT03303911 · 26 enrolled · United Kingdom
  3. Apr 17, 2018Phase 1 study in Smoking CessationNCT03509948 · 13 enrolled · United Kingdom
  4. Oct 15, 2018Phase 2 study in Smoking CessationNCT03709823 · 254 enrolled · United States
  5. Feb 19, 2019Phase 1 study in Smoking CessationNCT03848208 · 74 enrolled · Portugal
  6. Sep 25, 2020Phase 3 study in Smoking CessationNCT04576949 · 810 enrolled · United States
  7. Jan 12, 2022Phase 3 study in Smoking CessationNCT05206370 · 792 enrolled · United States
  8. Jun 20, 2022Phase 2 study in VapingNCT05431387 · 160 enrolled · United States
  9. Sep 30, 2022Phase 1 study in Smoking CessationNCT05566288 · 27 enrolled · Portugal
  10. Oct 18, 2022Phase 1 study in Renal InsufficiencyNCT05631938 · 44 enrolled · Portugal, Spain
  11. Aug 1, 2023Phase 1 study in Smoking CessationNCT05981768 · 30 enrolled · Portugal
  12. May 24, 2024Phase 3 study in Smoking CessationNCT06435221 · 479 enrolled · United States
  13. Jan 20, 2026Phase 3 study in Vaping CessationNCT07392125 · 800 planned

Ahead

  1. Nov 15, 2026Primary completion: phase 3 study in Vaping CessationNCT07392125

TargetBeta

“Neuronal acetylcholine receptor; alpha4/beta2 partial agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
VareniclinerulePfizerphase 445

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07392125Vaping Cessation3Not yet recruitingNov 15, 2026800
NCT06435221Smoking Cessation · United States3CompletedSep 29, 2025479
NCT05981768Smoking Cessation · Portugal1CompletedSep 21, 202330
NCT05631938Renal Insufficiency · Portugal, Spain1CompletedSep 4, 202344
NCT05566288Smoking Cessation · Portugal1CompletedDec 23, 202227
NCT05431387Vaping · United States2CompletedFeb 28, 2023160
NCT05206370Smoking Cessation · United States3CompletedMar 21, 2023792
NCT04576949Smoking Cessation · United States3CompletedDec 23, 2021810
NCT03848208Smoking Cessation · Portugal1CompletedSep 12, 201974
NCT03709823Smoking Cessation · United States2CompletedApr 23, 2019254
NCT03509948Smoking Cessation · United Kingdom1CompletedJun 10, 201813
NCT03303911Smoking Cessation · United Kingdom2TerminatedOct 5, 201826
NCT03268343Smoking Cessation · United Kingdom1CompletedAug 26, 201724

How it is read

Names in the registry

  • “Cytisinicline”, 6 entries
  • “Cytisine”, 3 entries
  • “cytisinicline”, 2 entries
  • “cytisine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.